194 related articles for article (PubMed ID: 19671805)
21. The predictive power of anti-cyclic citrullinated peptide antibodies: window into understanding gene/ environment/immunity interactions.
Lee W; Weisman MH
J Rheumatol; 2006 Jul; 33(7):1216-8. PubMed ID: 16821260
[No Abstract] [Full Text] [Related]
22. Diagnostic value of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis.
Mofidi M; Moghadam A
Saudi Med J; 2008 Aug; 29(8):1206-7. PubMed ID: 18690324
[No Abstract] [Full Text] [Related]
23. "KISS"--embracing routine patient assessment.
Uhlig T
J Rheumatol; 2009 Jun; 36(6):1096-8. PubMed ID: 19509085
[No Abstract] [Full Text] [Related]
24. Clinical value of second- and third-generation assays of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis.
Kitahara K; Takagi K; Kusunoki Y; Nishio S; Nozaki T; Inomata H; Takei M; Sawada S; Kawai S
Ann Rheum Dis; 2008 Jul; 67(7):1059-60. PubMed ID: 18556455
[No Abstract] [Full Text] [Related]
25. Likelihood ratios as a function of antibody concentration for anti-cyclic citrullinated peptide antibodies and rheumatoid factor.
Bossuyt X; Coenen D; Fieuws S; Verschueren P; Westhovens R; Blanckaert N
Ann Rheum Dis; 2009 Feb; 68(2):287-9. PubMed ID: 19139208
[No Abstract] [Full Text] [Related]
26. Production of anti-CCP antibodies and matrix metalloproteinase-3 by human rheumatoid arthritis synovial tissues using SCID mice.
Iwaki-Egawa S; Matsuno H; Ogawa Y; Watanabe Y
Ann Rheum Dis; 2005 Jul; 64(7):1094-5. PubMed ID: 15958770
[No Abstract] [Full Text] [Related]
27. A multidimensional health assessment questionnaire (MDHAQ) for all patients with rheumatic diseases to complete at all visits in standard clinical care.
Pincus T
Bull NYU Hosp Jt Dis; 2007; 65(2):150-60. PubMed ID: 17581111
[TBL] [Abstract][Full Text] [Related]
28. Duration of pre-rheumatoid arthritis anti-cyclic citrullinated peptide positivity is positively associated with age at seroconversion.
Bos WH; Nielen MM; Dijkmans BA; van Schaardenburg D
Ann Rheum Dis; 2008 Nov; 67(11):1642. PubMed ID: 18854513
[No Abstract] [Full Text] [Related]
29. Anti-citrullinated protein antibody response associated with synovial immune deposits in a patient with suspected early rheumatoid arthritis.
Willemze A; Ioan-Facsinay A; El-Gabalawy H
J Rheumatol; 2008 Nov; 35(11):2282-4. PubMed ID: 19004060
[No Abstract] [Full Text] [Related]
30. Very low prevalence of anti-CCP antibodies in rheumatoid factor-negative psoriatic polyarthritis.
Pasquetti P; Morozzi G; Galeazzi M
Rheumatology (Oxford); 2009 Mar; 48(3):315-6. PubMed ID: 19109316
[No Abstract] [Full Text] [Related]
31. Very early 'Rheumatoid' arthritis cohorts: limited by selection.
Inanc M
Rheumatology (Oxford); 2007 Feb; 46(2):185-7. PubMed ID: 17043049
[No Abstract] [Full Text] [Related]
32. [Do corticoids affect the anti-CCP titer?].
MMW Fortschr Med; 2015 Nov; 157(19):20. PubMed ID: 26953392
[No Abstract] [Full Text] [Related]
33. Why should rheumatologists collect patient self-report questionnaires in routine rheumatologic care?
Pincus T
Rheum Dis Clin North Am; 1995 May; 21(2):271-319. PubMed ID: 7631031
[TBL] [Abstract][Full Text] [Related]
34. How to collect an MDHAQ to provide rheumatology vital signs (function, pain, global status, and RAPID3 scores) in the infrastructure of rheumatology care, including some misconceptions regarding the MDHAQ.
Pincus T; Oliver AM; Bergman MJ
Rheum Dis Clin North Am; 2009 Nov; 35(4):799-812, x. PubMed ID: 19962624
[TBL] [Abstract][Full Text] [Related]
35. IgM-rheumatoid factor and anti-cyclic citrullinated peptide decrease by 50% during intensive treatment in early rheumatoid arthritis.
van Tuyl LH; Lems WF; Kerstens PJ; Voskuyl AE; Dijkmans BA; Boers M
Ann Rheum Dis; 2009 Oct; 68(10):1652-3. PubMed ID: 19748920
[No Abstract] [Full Text] [Related]
36. Optimization of high-throughput autoantibody profiling for the discovery of novel antigenic targets in rheumatoid arthritis.
Somers K; Stinissen P; Somers V
Ann N Y Acad Sci; 2009 Sep; 1173():92-102. PubMed ID: 19758137
[TBL] [Abstract][Full Text] [Related]
37. Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways.
Trouw LA; Haisma EM; Levarht EW; van der Woude D; Ioan-Facsinay A; Daha MR; Huizinga TW; Toes RE
Arthritis Rheum; 2009 Jul; 60(7):1923-31. PubMed ID: 19565507
[TBL] [Abstract][Full Text] [Related]
38. Association of severe inflammatory polyarthritis in primary Sjögren's syndrome: clinical, serologic, and HLA analysis.
Mohammed K; Pope J; Le Riche N; Brintnell W; Cairns E; Coles R; Bell DA
J Rheumatol; 2009 Sep; 36(9):1937-42. PubMed ID: 19487261
[TBL] [Abstract][Full Text] [Related]
39. [Antibodies against cyclic citrullinated peptide indicate rheumatoid arthritis].
Ljung L; Uddhammar A; Rantapää-Dahlqvist S
Lakartidningen; 2009 Aug 5-18; 106(32-33):1964-6. PubMed ID: 19764372
[No Abstract] [Full Text] [Related]
40. Prevalence and significance of isotypes of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis.
Syed RH; Gilliam BE; Moore TL
Ann Rheum Dis; 2008 Jul; 67(7):1049-51. PubMed ID: 18556446
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
